Pancreatic Cancer Research

ResearcherUniversity of California, IrvineActive in the last 2 years

Jennifer Brooke Valerin

Verified by OpenAlex author ID (good confidence, 0.85), identity_conf@1As of 7 November 2026

Matched on OpenAlex author ID A5025500000. Sources: OpenAlex.

Their work

Papers
8 (first author 0, last author 2)
Trials
0
Grants
0
Labs led
1
Collaborators
50
Papers, trials and grants by year

2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 3 papers · 2026: 2 papers

Papers 8

  1. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  2. Mevalonate Biosynthesis is a Metabolic Vulnerability of Gemcitabine-resistant Pancreatic Cancer. Co-author DOI 10.1053/j.gastro.2026.09.027↗
  3. Predicting Benefit of Neoadjuvant Chemotherapy and Elective Nodal Irradiation in Pancreatic Adenocarcinoma: A Supervised Machine Learning Approach. Co-author DOI 10.1002/cam4.71447↗
  4. Replacing Liposomal Irinotecan With Standard Irinotecan in Pancreatic Adenocarcinoma: Should We Follow Suit and Substitute Without Dispute? Co-author DOI 10.1097/mpa.0000000000002490↗
  5. Areas of Uncertainty in Pancreatic Cancer Surveillance: A Survey Across the International Pancreatic Cancer Early Detection (PRECEDE) Consortium. Co-author DOI 10.1200/po-25-00696↗
  6. The impact of the California state lockdown during the COVID-19 pandemic on management of patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1002/jso.27695↗
  7. Hereditary Cancer Clinics Improve Adherence to NCCN Germline Testing Guidelines for Pancreatic Cancer. Last author DOI 10.6004/jnccn.2023.7333↗
  8. BRCA-Mutated Pancreatic Cancer: From Discovery to Novel Treatment Paradigms. Last author DOI 10.3390/cancers14102453↗

Closest collaborators

The 25 strongest of 50 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Farshid Dayyani · 4 shared papers, 2022–2025 · strength 0.98
  2. Claudia Rosso · 2 shared papers, 2024 · strength 0.37
  3. Naomie Devico Marciano · 2 shared papers, 2022–2024 · strength 0.37
  4. May Thet Cho · 2 shared papers, 2022–2024 · strength 0.37
  5. Fa-Chyi Lee · 2 shared papers, 2022–2024 · strength 0.37
  6. Aditya Mahadevan · 1 shared paper, 2025 · strength 0.37
  7. David K. Imagawa · 1 shared paper, 2025 · strength 0.25
  8. Steven Neema Seyedin · 1 shared paper, 2025 · strength 0.25
  9. Garrett K. Harada · 1 shared paper, 2025 · strength 0.25
  10. Zeljka Jutric · 1 shared paper, 2025 · strength 0.25
  11. David S. Hong · 1 shared paper, 2025 · strength 0.25
  12. Christopher J. Halbrook · 1 shared paper, 2026 · strength 0.20
  13. Alexander Muir · 1 shared paper, 2026 · strength 0.20
  14. Chantal Allgöwer · 1 shared paper, 2026 · strength 0.20
  15. Austin D. Silva · 1 shared paper, 2026 · strength 0.20
  16. Tim Eiseler · 1 shared paper, 2026 · strength 0.20
  17. Rima Singh · 1 shared paper, 2026 · strength 0.20
  18. Kevin Christian Montecillo Gulay · 1 shared paper, 2026 · strength 0.20
  19. Alica K. Michels · 1 shared paper, 2026 · strength 0.20
  20. Alexander Kleger · 1 shared paper, 2026 · strength 0.20
  21. Thomas Theodor Werner Seufferlein · 1 shared paper, 2026 · strength 0.20
  22. Aimee L Edinger · 1 shared paper, 2026 · strength 0.20
  23. David Kuang-Fu Chang · 1 shared paper, 2026 · strength 0.20
  24. Hervé Tiriac · 1 shared paper, 2026 · strength 0.20
  25. Harshabad Singh · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.